Marinus Pharmaceuticals (NASDAQ:MRNS) Lifted to Hold at StockNews.com

Marinus Pharmaceuticals (NASDAQ:MRNS) was upgraded by equities researchers at StockNews.com from a “sell” rating to a “hold” rating in a research report issued on Wednesday.

Other equities research analysts have also recently issued reports about the company. HC Wainwright reiterated a “buy” rating and issued a $11.00 price target on shares of Marinus Pharmaceuticals in a research note on Wednesday, August 14th. LADENBURG THALM/SH SH lowered shares of Marinus Pharmaceuticals from a “buy” rating to a “neutral” rating in a research report on Wednesday, August 14th. Cantor Fitzgerald reissued an “overweight” rating and set a $13.00 target price on shares of Marinus Pharmaceuticals in a research report on Monday. Finally, Truist Financial reaffirmed a “buy” rating and issued a $10.00 price target on shares of Marinus Pharmaceuticals in a report on Tuesday, June 18th. Five research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat, Marinus Pharmaceuticals currently has a consensus rating of “Hold” and a consensus target price of $10.25.

Marinus Pharmaceuticals Price Performance

MRNS opened at $1.55 on Wednesday. The company has a market capitalization of $85.15 million, a price-to-earnings ratio of -0.59 and a beta of 1.13. The company has a current ratio of 2.28, a quick ratio of 2.15 and a debt-to-equity ratio of 5.68. Marinus Pharmaceuticals has a 12-month low of $1.05 and a 12-month high of $11.26. The business’s fifty day simple moving average is $1.36 and its 200-day simple moving average is $2.94.

Marinus Pharmaceuticals (NASDAQ:MRNS) last announced its earnings results on Tuesday, August 13th. The biopharmaceutical company reported ($0.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.59) by ($0.01). Marinus Pharmaceuticals had a negative net margin of 493.14% and a negative return on equity of 7,831.35%. The company had revenue of $8.06 million for the quarter, compared to the consensus estimate of $9.05 million. During the same period last year, the business posted ($0.61) EPS. On average, equities research analysts anticipate that Marinus Pharmaceuticals will post -1.88 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Trexquant Investment LP acquired a new stake in Marinus Pharmaceuticals during the 4th quarter worth about $553,000. Franklin Resources Inc. grew its holdings in Marinus Pharmaceuticals by 1.3% during the fourth quarter. Franklin Resources Inc. now owns 3,833,955 shares of the biopharmaceutical company’s stock worth $41,675,000 after acquiring an additional 49,589 shares during the period. Campbell & CO Investment Adviser LLC purchased a new position in Marinus Pharmaceuticals during the fourth quarter valued at approximately $1,146,000. Superstring Capital Management LP acquired a new position in Marinus Pharmaceuticals in the fourth quarter valued at approximately $5,027,000. Finally, Wellington Management Group LLP boosted its position in Marinus Pharmaceuticals by 54.8% in the 4th quarter. Wellington Management Group LLP now owns 241,299 shares of the biopharmaceutical company’s stock worth $2,623,000 after purchasing an additional 85,455 shares in the last quarter. Hedge funds and other institutional investors own 98.80% of the company’s stock.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.